Home › Research › Lewy body dementia
RNA-binding proteins with prion-like domains in health and disease
Harrison AF, Shorter J.. The Biochemical journal, 2017-04-07
Topic: Brain proteins, microglia and lab models
Plain-language summary
Approximately 70 human RNA-binding proteins (RBPs) contain a prion-like domain (PrLD). PrLDs are low-complexity domains that possess a similar amino acid composition to prion domains in yeast, which enable several proteins, including Sup35 and Rnq1, to form infectious conformers, termed prions. In humans, PrLDs contribute to RBP function and enable RBPs to undergo liquid-liquid phase transitions that underlie the biogenesis of various membraneless organelles. However, this activity appears to render RBPs prone to misfolding and aggregation connected to neurodegenerative disease. Indeed, numerous RBPs with PrLDs, including TDP-43 (transactivation response element DNA-binding protein 43), FUS (fused in sarcoma), TAF15 (TATA-binding protein-associated factor 15), EWSR1 (Ewing sarcoma breakpoint region 1), and heterogeneous nuclear ribonucleoproteins A1 and A2 (hnRNPA1 and hnRNPA2), have now been connected via pathology and genetics to the etiology of several neurodegenerative diseases, including amyotrophic lateral sclerosis, frontotemporal dementia, and multisystem proteinopathy. Here, we review the physiological and pathological roles of the most prominent RBPs with PrLDs. We also highlight the potential of protein disaggregases, including Hsp104, as a therapeutic strategy to combat the aberrant phase transitions of RBPs with PrLDs that likely underpin neurodegeneration.
What this study adds
Evidence grade: Low
This is a narrative review. About 70 human RNA-binding proteins carry a "prion-like domain" that helps them form liquid droplets inside cells as part of normal function. This review argues that the same property "appears to render" proteins such as TDP-43 and FUS prone to clumping, and these proteins have been linked through pathology and genetics to ALS, frontotemporal dementia and multisystem proteinopathy.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Harrison, A. F., & Shorter, J. (2017). RNA-binding proteins with prion-like domains in health and disease. The Biochemical journal. https://doi.org/10.1042/bcj20160499
Vancouver
Harrison AF, Shorter J. RNA-binding proteins with prion-like domains in health and disease. The Biochemical journal. 2017. doi:10.1042/bcj20160499. PMID: 28389532.
BibTeX
@article{harrison2017-28389532,
author = {Harrison, A. F. and Shorter, J.},
title = {{RNA-binding proteins with prion-like domains in health and disease}},
journal = {The Biochemical journal},
year = {2017},
doi = {10.1042/bcj20160499},
pmid = {28389532},
url = {https://doi.org/10.1042/bcj20160499}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- In humans, PrLDs contribute to RBP function and enable RBPs to undergo liquid-liquid phase transitions that underlie the biogenesis of various membraneless organelles.
- However, this activity appears to render RBPs prone to misfolding and aggregation connected to neurodegenerative disease.
- Indeed, numerous RBPs with PrLDs, including TDP-43 (transactivation response element DNA-binding protein 43), FUS (fused in sarcoma), TAF15 (TATA-binding protein-associated factor 15), EWSR1 (Ewing sarcoma breakpoint region 1), and heterogeneous nuclear ribonucleoproteins A1 and A2 (hnRNPA1 and hnRNPA2), have now been connected via pathology and genetics to the etiology of several neurodegenerative diseases, including amyotrophic lateral sclerosis, frontotemporal dementia, and multisystem proteinopathy.
- Here, we review the physiological and pathological roles of the most prominent RBPs with PrLDs.
- We also highlight the potential of protein disaggregases, including Hsp104, as a therapeutic strategy to combat the aberrant phase transitions of RBPs with PrLDs that likely underpin neurodegeneration.
Why it matters
About 70 human RNA-binding proteins carry a "prion-like domain" that helps them form liquid droplets inside cells as part of normal function. This review argues that the same property "appears to render" proteins such as TDP-43 and FUS prone to clumping, and these proteins have been linked through pathology and genetics to ALS, frontotemporal dementia and multisystem proteinopathy. It summarises earlier work and proposes, without testing, that disaggregase proteins such as Hsp104 could be a future treatment strategy. It does not study Alzheimer's disease or patients.
Study details
- Evidence strengthLow
How this study scored 50/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Biochemical journal) |
| Journal's citation record | 3 / 4 | Biochemical Journal: journal h-index 402 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2017 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 426 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 38.7 citations a year over 11 year(s) since 2017 |
| Impact for its field and year | 5 / 6 | Cited 28.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 8 other studies in this library |
| Still being cited | 3 / 4 | Cited 81 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author James Shorter: h-index 80 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Pennsylvania: institution h-index 1,859 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 28389532) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 35.
Later studies that cite this one
8 studies in the alzhub library list this one in their references.
Related studies in Lewy body dementia from nearby years
Also in Lewy body dementia
39 studies in the library are filed under Lewy body dementia with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Lewy body dementia hub.